Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kontafarma China Holdings Ltd ( (HK:1312) ) just unveiled an update.
Kontafarma China Holdings Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results for the year ended 31 December 2025. The board will also deliberate on the potential declaration of a final dividend, signalling possible returns to shareholders subject to the company’s financial performance and board approval.
The meeting underscores the group’s adherence to regulatory disclosure practices on the Hong Kong market and provides a timeline for investors anticipating full-year financial information. Any decision on a final dividend at this meeting could influence shareholder expectations and market perception of Kontafarma China’s earnings strength and capital allocation priorities.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates through a board comprising executive, non-executive and independent non-executive directors. The leadership is headed by Chairman and President Wang Feifei, supported by a financial controller and other directors overseeing the group’s corporate and financial governance.
Average Trading Volume: 1,181,139
Technical Sentiment Signal: Sell
Current Market Cap: HK$161.8M
Learn more about 1312 stock on TipRanks’ Stock Analysis page.